Fast-acting insulin aspart is as effective as insulin aspart for glucose control when used for continuous subcutaneous insulin infusion in adults with type 1 diabetes, results of the onset 5 study show.
A prespecified analysis of the CONCEPTT trial shows that pregnant women with type 1 diabetes who were using pumps at baseline did not achieve as good glycemic control as those using multiple daily injections.
The Tandem Basal-IQ predictive low-glucose suspend insulin delivery system significantly reduces the proportion of time adults and children spend in hypoglycemia during 24-hour usage, show findings from the randomized crossover PROLOG trial.
Advisory Board member Katharine Barnard scrutinizes the opinion that clinicians should be relying on glycemic outcomes when weighing the decision to prescribe a diabetes device.
Editorial Board member Sanjay Kalra presents his view on the march toward greater integration of digital health technologies and how traditional approaches to diabetes management are already changing.
Professor Moshe Phillip tells medwireNews why he believes the artificial pancreas will be of particular benefit for adolescents and young adults with type 1 diabetes.